Markets:

Overview

News

Currencies

International

Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

116.20 -4.14 (-3.44%)

Streaming Delayed Price Updated: 1:46 PM EDT, Mar 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 Next >

Goldman Sachs Bullish Forecast: 15% Increase in 2026 U.S. M&A Activity

Today 12:01 EDT

As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook,...

Via MarketMinute

2 Healthcare Stocks to Buy Before They Get Bought Out ↗

March 20, 2026

Abivax and Nektar Therapeutics are clinical-stage biotech companies that would make attractive buyout targets.

Via The Motley Fool

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

ABVX Soars Pre-Market On Reports Of $17.5 Billion Eli Lilly Takeover Interest ↗

January 12, 2026

Via Stocktwits

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This biotech develops Nanobody-based therapies targeting chronic inflammatory diseases in dermatology and rheumatology markets.

Via The Motley Fool

Topics Regulatory Compliance

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.

Via The Motley Fool

Topics Regulatory Compliance

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗

March 16, 2026

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Via The Motley Fool

This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗

March 16, 2026

Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.

Via The Motley Fool

Topics Regulatory Compliance

This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗

March 16, 2026

Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year ↗

March 10, 2026

Is there any upside left for this rising biotech?

Via The Motley Fool

2 Reasons Abivax Stock Could 10X by 2036 ↗

February 27, 2026

Could it be a biotech giant in the making?

Via The Motley Fool

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

February 21, 2026

From Abivax

Via GlobeNewswire

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Via The Motley Fool

Topics Regulatory Compliance

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 10, 2026

Could these two companies be biotech giants in the making?

Via The Motley Fool

Better Long-Term Buy: This Emerging Player or the Industry Leader? ↗

January 30, 2026

The choice between the two might come down to each investor's goals and risk tolerance.

Via The Motley Fool

Topics Intellectual Property

Prediction: This Healthcare Stock Could Soar by 72% in 2026 ↗

January 19, 2026

And the share price appreciation could happen pretty soon.

Via The Motley Fool

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

Abivax Provides 2026 Corporate Outlook

January 07, 2026

From Abivax

Via GlobeNewswire

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

Could This Potential Move Boost Eli Lilly's Prospects? ↗

December 31, 2025

The stock already looks unstoppable, and this move won't hurt its momentum.

Via The Motley Fool

The 2025 Growth Postgame: Analyzing the AI Supercycle and Preparing for the 2026 'Agentic' Pivot

December 26, 2025

As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗

December 24, 2025

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Via Stocktwits

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.